| name | ata-ch-before-gh-stim |
| description | Recommends treating central hypothyroidism before performing GH stimulation testing because CH may impair accurate diagnosis of GHD. Use when preparing for GH stimulation testing; triggers include patient requiring GH stimulation test with possible CH. |
Treat central hypothyroidism before GH stimulation testing
STEP 1 — Gather Information
Order serum free T4 (fT4) and TSH; assess for hypothyroid symptoms (fatigue, cold intolerance, weight gain, dry skin); confirm pituitary disease context (known pituitary lesion, surgery, radiation, or other hormone deficiencies).
STEP 2 — Rule In / Rule Out
If fT4 is below the laboratory reference range with a low, normal, or mildly elevated TSH in the setting of pituitary disease, rule in central hypothyroidism (CH); otherwise rule out CH.
STEP 3 — Classify or Stratify
If CH is ruled in, proceed to treatment; if CH is ruled out, proceed directly to GH stimulation testing.
STEP 4 — Decide
If CH present, initiate levothyroxine (L-T4) replacement at ~1.6 µg/kg/d, adjust dose to maintain fT4 in the mid‑upper reference range, monitor fT4 every 6–8 weeks, and perform GH stimulation testing once euthyroid; if CH absent, proceed directly to GH stimulation testing.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on TSH alone to diagnose or monitor CH; do not start GH stimulation testing without evaluating for CH; do not use L-T3, thyroid extracts, or other thyroid hormone formulations for CH; do not adjust L-T4 dosing based on TSH levels in CH; avoid overtreatment that may suppress TSH excessively and precipitate adrenal insufficiency if glucocorticoids are deficient.
Concrete Clinical Example
A 50‑year‑old man with a non‑functioning pituitary adenoma undergoes evaluation for suspected GHD. Prior to GH stimulation testing, fT4 is 0.8 ng/dl (low) and TSH is 4.2 µIU/ml (mildly elevated). He is diagnosed with CH, started on L-T4 100 µg daily, and after 8 weeks fT4 rises to 1.2 ng/dl (mid‑reference). GH stimulation testing is then performed, showing a peak GH of 3.1 µg/L, confirming GHD.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI: 10.1210/jc.2016-2118
